

SWIM ACROSS AMERICA MISSION:

" WE UNITE THE SWIMMING COMMUNITY BY HOSTING BENEFIT SWIMS THAT RAISE MONEY TO FUND LIFE SAVING CANCER RESEARCH AND CLINICAL TRIALS. "




The Aflac Cancer Center is ranked among the

TOP

pediatric cancer programs in the country.

Current SAA-Atlanta funding supports four young investigators and their research projects at the Aflac Cancer Center. Support for young investigators provides funding to a cohort of promising investigators and future research leaders to encourage and promote quality research in clinical oncology.



The intent is to fund physicians and provide career and project support for young, proven investigators in postdoctoral fellowships or who have recently achieved junior faculty positions and are committing their lives to the field of pediatric cancer to provide research with vibrant new ideas. Funding is designed to nurture young scientists in the pursuit of independent hypotheses and to enable them to develop the preliminary data necessary to successfully compete for major research grants.



The Aflac Cancer and Blood Disorders Center is ranked **#2 in the country**

for therapeutic Children's Oncology Group clinical trial enrollment. This is significant because a clinical trial is the very best shot for a cure.



Swim Across America Atlanta funds benefit the Aflac Cancer and Blood Disorders Center. Currently, funds are directed to support pediatric cancer research.

Nationally, Swim Across America has granted nearly

\$100 million

to fund cancer research and clinical trials.



Established in 2013, the Swim Across America Atlanta swim has donated more than

\$2.6 million

to the Aflac Cancer and Blood Disorders Center.

SAA Atlanta funds from 2013-2015 supported Dr. Tobey MacDonald to identify a specific driver of medulloblastoma tumor, the most common type of pediatric brain tumor. Dr. MacDonald and his team have identified a potential inhibitor to block tumor initiation and growth, and will be initiating a promising clinical trial with this drug for investigation in children with refractory brain tumors.



The Aflac Cancer Center treats more kids with brain tumors than anywhere else in the country.

From 2016 to 2018, SAA Atlanta funds supported the research of Dr. Doug Graham, Director of the Aflac Cancer Center. Dr. Graham and Deborah DeRyckere developed a promising new cancer drug, MRX-2843, which is special because it kills cancer cells and also reprograms the immune system to attack cancer cells.



Every Aflac Cancer Center physician is also a **researcher.**

The knowledge the Aflac Cancer Center gains is shared with all other pediatric cancer centers across the country.



The Aflac Cancer Center is the pediatric component of the Winship Cancer Institute of Emory University, the first and only comprehensive National Cancer Institute (NCI)- designated in Georgia.